Hidradenitis Suppurativa study: Ruxolitinib Cream
Official title Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
ClinicalTrials.gov ID: NCT07049575
What this study is testing
What is Ruxolitinib Cream?
An investigational topical cream being studied for hidradenitis suppurativa. It is designed to inhibit Janus kinase enzymes to reduce inflammation.
Also referred to as Ruxolitinib.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find the maximum amount of ruxolitinib cream that can be used safely.
- Who it's for
- Adults and adolescents who have hidradenitis suppurativa.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 75
You may be able to join if
- Diagnosis of HS for at least 6 months before screening visit.
- Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct...
- Total estimated treatment BSA \> 20% at screening and baseline.
- Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period.
- Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.
You likely can't join if
- Current or history of skin condition(s) other than HS that might confound the evaluation of HS; clinically uncontrolled cardiovascular disease
- Laboratory values outside of the protocol-defined ranges.
- Further exclusion criteria apply.
See the full eligibility criteria
- Diagnosis of HS for at least 6 months before screening visit.
- Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits.
- Total estimated treatment BSA \> 20% at screening and baseline.
- Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period.
- Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.
- Further apply.
- Current or history of skin condition(s) other than HS that might confound the evaluation of HS; clinically uncontrolled cardiovascular disease; thrombosis; certain cancers; certain infections
- Laboratory values outside of the protocol-defined ranges.
- Further exclusion criteria apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Phoenix, Arizona, United States
- Northridge, California, United States
- Orange, California, United States
- Thousand Oaks, California, United States
- Sanford, Florida, United States
- Sweetwater, Florida, United States
- Tampa, Florida, United States
- Columbus, Georgia, United States
- West Lafayette, Indiana, United States
- Bowling Green, Kentucky, United States
- Baton Rouge, Louisiana, United States
- Bolivar, Missouri, United States
- New York, New York, United States
- Fargo, North Dakota, United States
- Oklahoma City, Oklahoma, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Phoenix, Arizona, United States; Northridge, California, United States; Orange, California, United States; Thousand Oaks, California, United States; Sanford, Florida, United States; Sweetwater, Florida, United States and 9 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.